1 / 63

Pivotal Data on Myeloid Disorders From the 2013 Hematology Conference

Pivotal Data on Myeloid Disorders From the 2013 Hematology Conference. Activity Goals. Myelofibrosis. Newly Identified Biological Pathway May Aid Diagnosis, Treatment of MPNs. Ruxolitinib Escalated Dosing in MF. Characteristics of Patients With MF and Ruxolitinib Resistance.

marged
Download Presentation

Pivotal Data on Myeloid Disorders From the 2013 Hematology Conference

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pivotal Data on Myeloid Disorders From the 2013 Hematology Conference

  2. Activity Goals

  3. Myelofibrosis

  4. Newly Identified Biological Pathway May Aid Diagnosis, Treatment of MPNs

  5. Ruxolitinib Escalated Dosing in MF

  6. Characteristics of Patients With MF and Ruxolitinib Resistance

  7. Ruxolitinib Continues to Show Improved Survival in MF

  8. Momelotinib for MF: Long-term Results

  9. BMS-911543 in MF: Phase 1/2a Data

  10. Fedratinib in Patients With Previous Ruxolitinib

  11. Telomerase Inhibitor Imetelstat in MF

  12. Myeloproliferative Neoplasms

  13. Bone Marrow Features May Identify Early Polycythemia Vera (PV)

  14. History of Thrombosis at Diagnosis of ET

  15. Splanchnic Vein Thrombosis and MPNs

  16. LY2784544 for MF, PV, and ET

  17. AOP2014 for PV: Phase 1/2 Study

  18. AOP2014 for PV: Molecular Responses and Chromosomal Aberrations

  19. Chronic Myeloid Leukemia

  20. ENESTnd Trial Update: Nilotinib (NIL) vs Imatinib (IM)

  21. First Results of the LASOR Trial: Switching From IM to NIL

  22. STIM1 Study Long-term Follow-up

  23. STIM2 Study: Preliminary Results

  24. Immune Surveillance May Contribute to CML Control After TKI Discontinuation

  25. Myelodysplastic Syndromes

  26. Gene Mutation/Deletion Status Predicts Prognosis in Myelodysplastic Syndromes (MDSs)

  27. IPSS-R Predicts Response to Demethylating Agents (DMAs) in MDS

  28. IPSS-R Predicts Response to Erythropoietin-Stimulating Agents (ESAs)

  29. Response to Lenalidomide in Lower-risk MDS Better When Used as First-line Treatment

  30. Combination of Vorinostat + Azacitidine in MDS

  31. Genomic Changes Associated With Smoking

  32. Epoetin Alpha (EPO) Effective in Low-risk MDS

  33. Acute Lymphoblastic Leukemia

  34. CTL019 Cells Efficacious in Pilot Study in Relapsed/Refractory ALL

  35. CTL019 Cells Efficacious for Children With ALL Even After Allogeneic Stem Cell Transplant (SCT)

  36. Blinatumomab for Children With ALL

  37. Inotuzumab Plus Mini-hyper-CVD for Older Adults With ALL

  38. Pediatric Regimen for Adolescents and Young Adults With ALL: Toxicity Results

  39. Pediatric Regimens for Adolescents and Young Adults With ALL

  40. Acute Myeloid Leukemia

  41. Explanations for Progress in Survival in Core Binding Factor AML

  42. Dasatinib for Newly Diagnosed AML

  43. Sequential HAM Reduces Hematologic Toxicities in AML

  44. Clofarabine Salvage Therapy May Be Bridge to SCT in AML

  45. Selinexor (KPT-330) for AML: Phase 1 Data

  46. Abbreviations

  47. Abbreviations (cont)

  48. References

  49. References (cont)

  50. References (cont)

More Related